In a single institute experience with tamoxifen in the adjuvant setting for patients with breast DCIS, Guerrieri-Gonzaga et al. found that low-dose tamoxifen (5 mg per day) reduced ipsilateral recurrence in women aged > 50 years with ER-positive DCIS [41]. The gene discussed is ESR1; the disease is ductal breast carcinoma in situ.